This is the first competing continuation application for the Vanderbilt Cancer Center (VCC) CCSG. The VCC is a matrix center within Vanderbilt University Medical Center (VUMC), and the VCC integrates the cancer-related expertise and resources of the School of Medicine, Vanderbilt University Hospital, and The Vanderbilt Clinic within VUMC; the fully integrated Veterans Administration Medical Center (VAMC); and the Departments of Chemistry and Molecular Biology in the School of Arts and Sciences. All facilities are located in close proximity on the same campus, a situation that promotes interactions, sharing of resources, and collaborations. Established in 1993, the VCC functions as an organizational unit with a supradepartmental status. The VCC s specific authorities and responsibilities are: 1) to coordinate and integrate the cancer and cancer-related activities of Vanderbilt University; 2) to conduct, support and enhance cancer research and to integrate cancer-related activities throughout the University; 3) to integrate, develop and conduct cancer education programs; and 4) to coordinate and integrate the care of cancer patients at VUMC and VAMC. The research objectives are accomplished through seven research programs: Signal Transduction and Cell Proliferation, Cancer Genetics and Genomics, Host Tumor Interactions, Gastrointestinal Cancer, Breast Cancer, Cancer Prevention, and Experimental Therapeutics. Because of new directions and opportunities, the research programs have been reorganized and refined. Significantly, a Cancer Prevention Research Program has been developed with the anticipation of obtaining comprehensive status. Following the reorganization of the research programs, the entire membership of the VCC was evaluated by a stringent set of criteria, and members were assigned to research programs by the individual program leaders or their membership terminated. Eleven shared resources are proposed representing reorganization of clinical research-related shared resources, establishment of two new ones and termination of one. Since the submission of our initial CCSG application in 1994, the VCC has participated in the recruitment of 29 faculty members to enhance programs or shared resources. Start-up funding for 13 of these faculty was provided by the VCC; the remaining 16 were supported initially by institutional or departmental funds with the VCC identifying or helping to identify the need and playing a major role in the recruitment process.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA068485-08S1
Application #
6801745
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1995-09-05
Project End
2004-08-31
Budget Start
2003-09-12
Budget End
2004-08-31
Support Year
8
Fiscal Year
2003
Total Cost
$139,737
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Hebron, Katie E; Li, Elizabeth Y; Arnold Egloff, Shanna A et al. (2018) Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis. Sci Rep 8:3208
Bangaru, Sandhya; Zhang, Heng; Gilchuk, Iuliia M et al. (2018) A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun 9:2669
Means, Anna L; Freeman, Tanner J; Zhu, Jing et al. (2018) Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cell Mol Gastroenterol Hepatol 6:257-276
Du, Zhenfang; Lovly, Christine M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58
Zhang, Qin; Jeppesen, Dennis K; Higginbotham, James N et al. (2018) Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells. Cell Mol Gastroenterol Hepatol 5:627-629.e6
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Kook, Seunghyi; Qi, Aidong; Wang, Ping et al. (2018) Gene-edited MLE-15 Cells as a Model for the Hermansky-Pudlak Syndromes. Am J Respir Cell Mol Biol 58:566-574
Choksi, Yash A; Reddy, Vishruth K; Singh, Kshipra et al. (2018) BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability. Mucosal Immunol 11:1363-1374
Cooke, Allison L; Morris, Jamie; Melchior, John T et al. (2018) A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL. J Lipid Res 59:1244-1255

Showing the most recent 10 out of 2462 publications